Scarica l'app Stockscreener
227.99
0.11%
-0.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
Is AbbVie Inc. stock resilient to inflationProduct Launch & Fast Exit and Entry Strategy Plans - newser.com
How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts - Yahoo Finance
Why AbbVie Inc. (4AB) stock stays on top picksWeekly Trade Report & Weekly Breakout Watchlists - newser.com
AbbVie Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com
Published on: 2025-10-24 20:28:34 - newser.com
AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment? - TipRanks
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? - sharewise.com
Is AbbVie Inc. stock a buy on dipsJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - sharewise.com
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - The Motley Fool
Wolfe Research Adjusts AbbVie Price Target to $275 From $235, Maintains Outperform Rating - MarketScreener
Can AbbVie Inc. stock attract analyst upgradesMarket Risk Report & Reliable Price Breakout Signals - newser.com
Will AbbVie Inc. stock attract more institutional investors2025 Retail Activity & Stepwise Trade Signal Implementation - newser.com
How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressureEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation - Insider Monkey
AbbVie Inc. (ABBV): A Bull Case Theory - Insider Monkey
AbbVie Up More Than 30% in 6 Months: How to Play the Stock - The Globe and Mail
YieldBoost AbbVie From 2.9% To 6.9% Using Options - Nasdaq
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance
Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
How sentiment analysis helps forecast AbbVie Inc.Global Markets & Community Trade Idea Sharing Platform - newser.com
Can AbbVie Inc. stock withstand economic slowdownBull Run & Technical Pattern Based Signals - newser.com
Measuring AbbVie Inc.’s beta against major indices2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
How AbbVie Inc. (4AB) stock performs in volatility spikesJuly 2025 Technicals & Fast Exit Strategy with Risk Control - newser.com
Will AbbVie Inc. stock outperform Dow JonesInsider Selling & Stepwise Trade Execution Plans - newser.com
Why AbbVie Inc. stock is in analyst buy zoneQuarterly Trade Summary & Daily Entry Point Alerts - newser.com
Can AbbVie Inc. stock surprise markets with earningsTrade Signal Summary & Daily Momentum Trading Reports - newser.com
AbbVie's Rinvoq Beats Humira in Key Arthritis Trial - Yahoo Finance
Fund Update: Bank Pictet & Cie (Europe) AG added 112,421 shares of ABBVIE (ABBV) to their portfolio - Quiver Quantitative
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Alpha Cognition Inc (ACOG) and Exelixis (EXEL) - The Globe and Mail
Bernstein Remains a Hold on AbbVie (ABBV) - The Globe and Mail
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients - AbbVie News Center
How AbbVie Inc. stock compares with tech leadersQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - newser.com
Five things for pharma marketers to know for Tuesday, October 21, 2025 - Medical Marketing and Media
Will AbbVie Inc. stock maintain strong growthRate Cut & High Conviction Buy Zone Alerts - newser.com
How AbbVie Inc. stock performs in rising dollar environment2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 2025Weekly Loss Report & Risk Adjusted Swing Trade Ideas - newser.com
Lobbying Update: $980,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
Is AbbVie Inc. a candidate for recovery play2025 Top Decliners & Weekly High Potential Stock Alerts - newser.com
AbbVie's Rinvoq (ABBV) Outperforms Humira in Key Rheumatoid Arthritis Trial - GuruFocus
AbbVie's Rinvoq beats Humira in head-to-head rheumatoid arthritis trial - Seeking Alpha
AbbVie's Rinvoq shows superiority over Humira in head-to-head arthritis study - Reuters
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings - sharewise.com
Endometriosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma - Barchart.com
Guggenheim Raises Price Target for AbbVie (ABBV) to $242 | ABBV Stock News - GuruFocus
AbbVie (ABBV) Reports Positive Phase 3b/4 Study Results for Upad - GuruFocus
1.08%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):